GlassScriptPhysician profile
Adriana B Cano
NPI 1730184235
$5,192.16
in general payments reported to CMS, 2019-2025
28 companies · $39.31 in 2025
The $39.31 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $115 · 2021: $524 · 2022: $404 · 2023: $2,048 · 2024: $1,634 · 2025: $39.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,874 · Consulting Fee: $815 · Education: $33.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,873.98 |
| Consulting Fee | $814.50 |
| Education | $33.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,152.95 | 2021-2024 | Benlysta, Jesduvroq |
| Opko Pharmaceuticals, LLC | $503.05 | 2019-2024 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $463.91 | 2019-2024 | Farxiga |
| Aurinia Pharma U.S., INC. | $420.86 | 2021-2024 | Lupkynis |
| Fresenius USA Marketing, INC. | $411.17 | 2019-2024 | Velphoro, Korsuva |
| Mallinckrodt Hospital Products INC. | $303.79 | 2020-2024 | Acthar |
| Amgen INC. | $294.18 | 2021-2024 | Krystexxa, Tavneos, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $233.33 | 2019-2024 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $219.91 | 2021-2024 | |
| Travere Therapeutics, INC. | $178.38 | 2023-2024 | |
| Horizon Therapeutics Plc | $140.24 | 2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $132.11 | 2024-2025 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $115.72 | 2020-2022 | |
| Lilly USA, LLC | $84.85 | 2024-2025 | Jardiance |
| Vifor Pharma, INC. | $79.46 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.15 | 2024 | Jardiance |
| Novo Nordisk INC | $70.68 | 2021-2024 | Ozempic |
| Ardelyx, INC. | $50.19 | 2024 | Ibsrela |
| Genzyme Corporation | $43.90 | 2019 | |
| Renalytix Ai, INC. | $41.01 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Tactile Systems Technology INC | $32.83 | 2022 | |
| Mallinckrodt Enterprises LLC | $27.37 | 2019 | |
| Pfizer INC. | $24.46 | 2024 | |
| Recor Medical INC | $23.93 | 2024 | Paradise Renal Denervation System |
| Calliditas Therapeutics US INC. | $23.68 | 2022 | |
| Shire North American Group INC | $18.83 | 2019 | |
| Bard Peripheral Vascular, INC. | $15.96 | 2021 | |
| Dexcom, INC. | $14.26 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adriana Cano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.